![]() |
市場調查報告書
商品編碼
1518602
2024-2032 年按測試類型(基於 ELISA 的測試、基於 RT-PCR 的測試、登革熱 IgG/IgM 快速測試等)、最終用戶(醫院、診斷中心等)和地區分類的登革熱測試市場報告Dengue Testing Market Report by Test Type (ELISA-based Tests, RT-PCR based Tests, Dengue IgG/IgM Rapid Test, and Others), End User (Hospitals, Diagnostic Centers, and Others), and Region 2024-2032 |
2023 年,IMARC Group登革熱檢測市場規模達到 5.842 億美元。
登革熱,也稱為斷骨熱,是一種透過受感染的埃及斑蚊叮咬傳播的病毒感染。它會導致關節和肌肉疼痛、高燒、腹痛、嘔吐、呼吸困難、皮膚濕冷、頭痛、眼後疼痛、疲勞、皮疹以及鼻子和牙齦輕微出血。透過登革熱檢測進行診斷,包括酵素連結免疫吸附測定 (ELISA)、RT-PCR 和登革熱 IgG/IgM 快速檢測。登革熱測試由醫療專業人員使用血液樣本進行,以識別登革熱病毒的不同血清型。
由於全球暖化和全球蚊子繁殖地的加劇,登革熱病例不斷增加,這是推動市場的主要因素之一。此外,準確有效的登革熱診斷在臨床護理中發揮關鍵作用。它協助發病機制、臨床試驗、疫情控制、學術研究、疫苗開發、監測活動、重症病例的早期發現以及與其他傳染病的病例確認和鑑別診斷。這些好處正在積極影響世界各地對登革熱檢測的需求。除此之外,由於生活條件差,世界各地人口稠密的地區更容易生病。再加上由於缺乏公眾意識而導致的衛生和廢物管理技術較差,正在刺激市場的成長。此外,醫療保健專業人員鼓勵人們透過自我保護和殺蟲劑熱霧來預防登革熱。再加上幾個國家政府組織的宣傳活動,正在推動市場的成長。其他促進成長的因素包括快速城市化和醫療保健行業的技術進步。此外,主要市場參與者正在廣泛投資於研發(R&D)活動,以開發高效且具成本效益的登革熱檢測試劑盒。
The global dengue testing market size reached US$ 584.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 879.0 Million by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.
Dengue, also known as breakbone fever, is a viral infection that spreads through the bite of an infected Aedes aegypti mosquito. It causes ache in the joints and muscles, high fever, abdominal pain, vomiting, difficulty in breathing, clammy and cold skin, headache, pain behind the eyes, fatigue, rashes, and mild bleeding in the nose and gums. It is diagnosed via dengue testing, which includes enzyme-linked immunosorbent assay (ELISA), RT-PCR, and dengue IgG/IgM rapid tests. Dengue testing is performed by medical professionals using a blood sample to identify the different serotypes of the dengue virus.
The growing cases of dengue on account of the rising global warming and breeding sites of mosquitos across the globe represents one of the major factors driving the market. Moreover, accurate and efficient diagnosis of dengue plays a pivotal role in clinical care. It assists in pathogenesis, clinical trials, outbreak control, academic research, vaccine development, surveillance activities, early detection of severe cases, and case confirmation and differential diagnosis with other infectious diseases. These benefits are positively influencing the demand for dengue testing around the world. Besides this, densely populated areas worldwide are more disease-prone due to low living conditions. This, along with poor sanitation and waste management techniques due to lack of public awareness, is stimulating the growth of the market. In addition, healthcare professionals are encouraging people to prevent dengue by self-protection and thermal fogging of insecticides. This, coupled with awareness campaigns organized by the government of several countries, is propelling the growth of the market. Other growth-inducing factors are rapid urbanization and technological advancements in the healthcare industry. Furthermore, key market players are extensively investing in research and development (R&D) activities to develop highly efficient and cost-effective dengue test kits.
IMARC Group provides an analysis of the key trends in each sub-segment of the global dengue testing market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on test type and end user.
ELISA-based Tests
RT-PCR based Tests
Dengue IgG/IgM Rapid Test
Others
Hospitals
Diagnostic Centers
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abnova Corporation, CerTest Biotec S.L., DiaSorin S.p.A., F. Hoffmann-La Roche AG, InBios International Inc., NovaTec Immundiagnostica GmbH, OriGene Technologies Inc., PerkinElmer Inc., Quest Diagnostics Incorporated and Thermo Fisher Scientific Inc.